Riociguat was associated with increases in right ventricular work, right ventricular work index, stroke volume index, stroke volume index, and cardiac efficiency in patients with pulmonary arterial hypertension.
Higher doses of treprostinil significantly delayed time to first pulmonary arterial hypertension-related or all-cause hospitalization.
Recent data suggest that the endothelin receptor antagonist macitentan can be used to target the endothelin pathway in patients with portopulmonary hypertension.
In some patients at risk for pulmonary hypertension, left ventricular end diastolic pressure measurement with standard right heart catheterization should be used.
Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.
United Therapeutics announced that the Phase 3 trial of Orenitram for PAH has met its primary endpoint of delayed time to first clinical worsening event.
Segmental pulmonary hypertension can result from several conditions, such as complex pulmonary atresia, hemitruncus arteriosus, absence/atresia of a single pulmonary artery, and an anomalous pulmonary artery from the aorta feeding a single lung segment.
Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.
Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.
Increased pulmonary pressures, right ventricular dysfunction, and a stiffer pulmonary vascular bed were typical characteristics of early pulmonary vascular disease onset in young adults who were born preterm.
Neopterin was predictive of clinical deterioration in patients with pulmonary arterial hypertension and inoperable CTEPH.
Although there were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.
Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.
The Pediatric Index Pulmonary Hypertension Intensive Care Mortality model was compared with the Pediatric Risk of Mortality 2 and 3 models to determine the best model for predicting mortality.
The fractal dimension of right ventricular trabecular complexity was a good reproducible marker of remodeling in pulmonary hypertension.
Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.
Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.
Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.
A 72-year-old man with hypertension and paroxysmal atrial fibrillation presents to the emergency department because he has been experiencing worsening shortness of breath.
After iron supplementation, patients with cyanosis experienced significant improvements in hemoglobin concentration, hematocrit, mean corpuscular volume, ferritin, and transferrin saturation.
In patients with end-stage interstitial lung disease, there was a higher rate of survival to transplantation with venoarterial extracorporeal membrane oxygenation.
Strong relationships were observed between health-related quality-of-life scores and factors such as breathlessness, fatigue, depression, anxiety, and sleep in pulmonary hypertension.
Double lung transplantation appears to offer superior survival outcomes to single lung transplantation in patients with interstitial pulmonary fibrosis who are younger than 70 years.
The interaction of age and obesity with respect to survival in pulmonary arterial hypertension showed an increased risk for mortality in young adults who were morbidly obese.
The majority of deaths in patients with systemic sclerosis-associated pulmonary arterial hypertension occurred within 4 years of diagnosis.
Precapillary pulmonary hypertension and obstructive sleep apnea may be causative factors for central sleep apnea and pulmonary hypertension, respectively.
There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.
Researchers raise issues regarding interpretation of clinical trial results in the field of pulmonary arterial hypertension.
Researchers modified the inhalation technique of iloprost in a patient with pulmonary arterial hypertension by attaching a nasal cannula to the inhalator's inlet port, shortening the administration duration.
The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.